Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200254 | 0.94 | CYP2D6 (0.67) | CYP2D6KCNH2S1PR1S1PR3POLB | |
| SCHEMBL3210270 | 0.90 | CYP2D6 (0.56) | CYP2D6KCNH2CA1CA2CA7 | |
| SCHEMBL15890759 | 0.88 | FFAR1 (0.62) | CYP2D6S1PR1S1PR3LTA4H | |
| SCHEMBL3208902 | 0.88 | KDM4E (0.54) | CYP2D6S1PR1S1PR3POLBKMT2A | |
| Trifluoroacetic Acid SCHEMBL947966 | 0.87 | CYP2D6 (0.60) | CYP2D6KCNH2S1PR1S1PR3LTA4H | |
| SCHEMBL15891006 | 0.87 | S1PR1 (0.70) | CYP2D6S1PR1S1PR3LTA4H | |
| SCHEMBL15890906 | 0.86 | HPGD (0.57) | CYP2D6KCNH2S1PR1S1PR3 | |
| Trifluoroacetic Acid SCHEMBL948321 | 0.86 | CYP2D6 (0.61) | CYP2D6KCNH2S1PR1POLBPPARG | |
| SCHEMBL1206748 | 0.86 | LMNA (0.68) | KMT2ALMNAL3MBTL1PPARGPPARA | |
| Trifluoroacetic Acid SCHEMBL947011 | 0.85 | CYP2D6 (0.61) | CYP2D6KCNH2S1PR1S1PR3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CYP2D6 4781/4885KCNH2 4261/4885CA1 4651/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | CYP2D6 4722/4885KCNH2 1345/4885CA1 1466/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CYP2D6 4804/4885KCNH2 4324/4885CA1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.